You Searched For:

MycoZap™ Mycoplasma Elimination Reagent The MycoZap™ Reagent can eliminate detectable mycoplasma contamination in as few as 4 days and has been optimized to clear mycoplasma with minimal toxic effects on the infected cells. It eliminates mycoplasm...

Final fill for cell therapy The cell therapy drug product is configured in different ways depending on the required delivery of the cells/tissues. For example, delivery of chondrocytes for cartilage repair is administered by an injection. Expanded...

PanReac AppliChem Decontamination Decontamination and Control Reagents It is important to work as cleanly as possible. Contamination is very frustrating for the scientist and in the end also very expensive. PanReac AppliChem offers a variety of pr...

Final fill for cell therapy The cell therapy drug product is configured in different ways depending on the required delivery of the cells/tissues. For example delivery of chondrocytes for cartilage repair is administered by an injection. Expanded ...

微生物基重组蛋白的上游加工 利用微生物发酵来开发和制造重组蛋白的优势，例如表达不需要翻译后修饰的蛋白，因为像大肠杆菌这样的微生物系统缺乏翻译后机制。 Avantor的产品组合解决了发酵介质和补充剂的需求。 我们的发酵产品支持细胞生长和生产率，同时满足所需的质量和性能参数，允许从研发、试点规模到生产规模的无缝过渡。 主要回收、浓缩和澄清所需的离心机和试剂是可用的。 一旦您的最佳内部开发的生产基础介质确定，期待Avantor定制制造您的液体或干格式的介质，并包装他们，以允许高效转移到您的生物反...

Downstream purification for vaccines During subsequent steps for vaccine concentration and clarification, followed by passage through several filtration steps and chromatography columns, it is critical that vaccine purity, potency, and consistency...

Upstream processing for cell therapy 他の生物製剤に関連する生産量（例：mAb：2000L〜10000L）と比較して、細胞療法の生産量はより一般的に1L〜10Lです。 品質パラメータも異なります。 細胞療法は、最大の力価とタンパク質の品質を追求する代わりに、送達のための最大の細胞用量と、投与される細胞/組織の機能に焦点を合わせています。 したがって、培地、サプリメント、バイオリアクターシステム、および開始細胞の品質をカバーする上流の生産パラメーターは非常...

MycoAlert PLUS™ The MycoAlert™ PLUS Mycoplasma Detection Kit is the next generation MycoAlert™ Kit which provides higher light out put and this allows for use with less sensitive plate luminometers or multifunctional readers testing of unused medi...

Final fill for cell therapy The cell therapy drug product is configured in different ways depending on the required delivery of the cells/tissues. For example delivery of chondrocytes for cartilage repair is administered by an injection. Expanded ...

Final fill for cell therapy The cell therapy drug product is configured in different ways depending on the required delivery of the cells/tissues. For example delivery of chondrocytes for cartilage repair is administered by an injection. Expanded ...

Final fill for mAbs Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO Cla...

Final fill for vaccines Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO...

Downstream purification for vaccines During subsequent steps for vaccine concentration and clarification followed by passage through several filtration steps and chromatography columns it is critical that vaccine purity potency and consistency be ...

Final fill for vaccines Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO...

Final fill for vaccines Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO...